S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:STOK

Stoke Therapeutics News Headlines

$60.62
+1.36 (+2.29 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$57.79
Now: $60.62
$61.35
50-Day Range
$58.20
MA: $62.49
$69.81
52-Week Range
$15.82
Now: $60.62
$71.58
Volume59,617 shs
Average Volume127,575 shs
Market Capitalization$2.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.63

Headlines

Stoke Therapeutics (NASDAQ STOK) News Headlines Today

Source:
SourceHeadline
Stephen J. Tulipano Sells 30,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockStephen J. Tulipano Sells 30,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock
americanbankingnews.com - February 24 at 9:14 PM
Stoke Therapeutics Inc (STOK) CFO Stephen J Tulipano Sold $1.8 million of SharesStoke Therapeutics Inc (STOK) CFO Stephen J Tulipano Sold $1.8 million of Shares
finance.yahoo.com - February 24 at 8:46 PM
Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,000 Shares of StockInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,000 Shares of Stock
americanbankingnews.com - February 23 at 6:42 PM
FY2020 Earnings Estimate for Stoke Therapeutics, Inc. (NASDAQ:STOK) Issued By WedbushFY2020 Earnings Estimate for Stoke Therapeutics, Inc. (NASDAQ:STOK) Issued By Wedbush
americanbankingnews.com - February 12 at 6:34 AM
Equities Analysts Set Expectations for Stoke Therapeutics, Inc.s FY2025 Earnings (NASDAQ:STOK)Equities Analysts Set Expectations for Stoke Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:STOK)
americanbankingnews.com - February 11 at 9:29 AM
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from AnalystsStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - February 11 at 5:06 AM
Wedbush Lowers Stoke Therapeutics (NASDAQ:STOK) to NeutralWedbush Lowers Stoke Therapeutics (NASDAQ:STOK) to Neutral
americanbankingnews.com - February 10 at 7:48 AM
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 5.8%Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 5.8%
americanbankingnews.com - February 8 at 9:38 PM
Stoke Therapeutics (NASDAQ:STOK) Trading 6.4% Higher Stoke Therapeutics (NASDAQ:STOK) Trading 6.4% Higher
americanbankingnews.com - February 2 at 7:38 PM
Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceMersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:19 AM
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated MilestonesMersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
finance.yahoo.com - January 5 at 1:13 PM
MRSN May 2021 17.500 putMRSN May 2021 17.500 put
uk.finance.yahoo.com - January 1 at 3:35 AM
MRSN Jan 2021 12.500 putMRSN Jan 2021 12.500 put
uk.finance.yahoo.com - December 31 at 10:08 PM
MRSN Jan 2021 22.500 putMRSN Jan 2021 22.500 put
uk.finance.yahoo.com - December 31 at 10:08 PM
STOK Jan 2021 50.000 putSTOK Jan 2021 50.000 put
au.finance.yahoo.com - December 29 at 12:38 AM
STOK Feb 2021 65.000 callSTOK Feb 2021 65.000 call
au.finance.yahoo.com - December 28 at 2:33 PM
STOK Jan 2021 30.000 callSTOK Jan 2021 30.000 call
au.finance.yahoo.com - December 27 at 10:16 PM
STOK Feb 2021 20.000 callSTOK Feb 2021 20.000 call
au.finance.yahoo.com - December 27 at 10:16 PM
Health Check: How Prudently Does Mersana Therapeutics (NASDAQ:MRSN) Use Debt?Health Check: How Prudently Does Mersana Therapeutics (NASDAQ:MRSN) Use Debt?
finance.yahoo.com - December 25 at 12:35 PM
Mersana Therapeutics to Host Virtual Analyst and Investor EventMersana Therapeutics to Host Virtual Analyst and Investor Event
finance.yahoo.com - December 17 at 9:46 AM
Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual MeetingStoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting
finance.yahoo.com - December 4 at 1:55 PM
Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical OfficerMersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer
finance.yahoo.com - November 30 at 2:55 PM
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesStoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 24 at 4:59 PM
Stoke Therapeutics prices $97.5M public offeringStoke Therapeutics prices $97.5M public offering
seekingalpha.com - November 20 at 3:09 AM
Stoke Therapeutics -2.7% AH, proposes public offeringStoke Therapeutics -2.7% AH, proposes public offering
seekingalpha.com - November 18 at 8:53 PM
STOK Crosses Above Average Analyst TargetSTOK Crosses Above Average Analyst Target
nasdaq.com - November 12 at 9:59 PM
Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceStoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
businesswire.com - November 9 at 7:40 AM
Have Insiders Been Buying Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares?Have Insiders Been Buying Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares?
finance.yahoo.com - November 5 at 12:29 PM
‘The aim is to get Stoke City back to the Premier League’ – Stand-in captain Mikel‘The aim is to get Stoke City back to the Premier League’ – Stand-in captain Mikel
msn.com - October 24 at 9:12 AM
Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual MeetingMersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
finance.yahoo.com - October 20 at 7:37 AM
SRNE Oct 2020 20.000 callSRNE Oct 2020 20.000 call
finance.yahoo.com - October 17 at 5:39 PM
Stoke Therapeutics advances STK-001 dosing in early-stage study in a rare form of childhood epilepsyStoke Therapeutics advances STK-001 dosing in early-stage study in a rare form of childhood epilepsy
seekingalpha.com - October 7 at 8:23 AM
Why Mersana Therapeutics' (NASDAQ:MRSN) CEO Pay MattersWhy Mersana Therapeutics' (NASDAQ:MRSN) CEO Pay Matters
finance.yahoo.com - September 21 at 1:43 PM
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth PlansStoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - September 15 at 1:23 PM
Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual CongressMersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress
finance.yahoo.com - September 10 at 10:06 AM
Dean Ashton on Stoke interest of 2009: I was in no fit state to move anywhereDean Ashton on Stoke interest of 2009: I was in no fit state to move anywhere
msn.com - September 8 at 6:40 PM
Three paintings set to be put in Stoke STUDENT FLAT are worth £20,000Three paintings set to be put in Stoke STUDENT FLAT are worth £20,000
msn.com - September 5 at 9:22 AM
What does can they do it on a cold rainy night in Stoke mean? Messi phrase explainedWhat does 'can they do it on a cold rainy night in Stoke' mean? Messi phrase explained
msn.com - September 5 at 4:21 AM
Stokes STK-001 preclinical data published in a science journalStoke's STK-001 preclinical data published in a science journal
seekingalpha.com - August 26 at 6:08 PM
Stokes STK-001 shows encouraging action in preclinical studyStoke's STK-001 shows encouraging action in preclinical study
seekingalpha.com - August 26 at 6:08 PM
Stoke Therapeutics EPS misses by $0.04Stoke Therapeutics EPS misses by $0.04
seekingalpha.com - August 10 at 10:26 AM
Stoke Therapeutics IncStoke Therapeutics Inc
reuters.com - August 9 at 8:29 AM
Stoke Therapeutics to Present at Upcoming Investor Conferences in AugustStoke Therapeutics to Present at Upcoming Investor Conferences in August
benzinga.com - August 4 at 1:28 PM
BRIEF-Stoke Therapeutics Reports Q1 Financial ResultsBRIEF-Stoke Therapeutics Reports Q1 Financial Results
www.reuters.com - May 15 at 10:45 PM
Stoke Therapeutics Inc.Stoke Therapeutics Inc.
www.barrons.com - May 15 at 5:45 PM
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesStoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
finance.yahoo.com - May 15 at 7:44 AM
Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve DisorderStoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
finance.yahoo.com - May 12 at 2:26 PM
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business UpdatesStoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
finance.yahoo.com - March 23 at 1:00 PM
Stoke Therapeutics to Present at 40th Annual Cowen Health Care ConferenceStoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
finance.yahoo.com - February 24 at 9:31 AM
Slaven Bilic handed big West Brom boost ahead of Stoke City clashSlaven Bilic handed big West Brom boost ahead of Stoke City clash
www.msn.com - January 18 at 12:31 PM
This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.